ArticleClinical and translational radiation oncology2026
Chemoradiation of glioblastoma cells alters expression of activation and immune checkpoint molecules on type 1 and 2 dendritic cells and impacts on subsequent T cell proliferation.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Glioblastoma is the most aggressive malignant brain tumor with an overall poor prognosis despite advanced chemoradiation approaches. Immunotherapeutic strategies have not been beneficial to date. Even being present only at low level in the brain, dendritic cells (DCs) have the potential to promote anti-tumor immune responses. In this study we aimed to gain insight into the interactions between glioblastoma tumor cells, DCs and T cells to understand the molecular and cellular mechanisms driving immune alterations in glioblastoma during standard treatments for optimizing immune therapies in the future. Material and methods: Impact of the conventional chemoradiation (RCT) treatment scheme of glioblastoma cells on conventional DCs type 1 and 2 (cDC) was tested in a syngeneic murine cell culture setting. GL261-luc2 glioblastoma cells were treated and subsequently co-cultured with cDC1-like and cDC2-like cells. Their immunological status was determined as follows: Expression of activation and immune checkpoint markers was quantified via flow cytometry. Cytokine and chemokine secretion was measured by bead-based immunoassays. Mixed lymphocyte reactions with either CD4+ or CD8+ T cells were performed to determine the potential of cDCs in stimulating T cell proliferation. Results: The cellular contact of cDC1-like cells with RCT-treated glioblastoma cells shifted their immune phenotype to a more activated one, whereas the activation of cDC2-like cells was limited. Furthermore, the extracellular profile of inflammatory and immunoregulatory cytokines and chemokines was highly dependent on the tumor cell treatment scheme in co-culture with cDC1-like cells, with the most pronounced effect after RCT. These modifications in the activation status of cDC1- and cDC2-like cells after tumor cell contact subsequently resulted in significantly enhanced CD8 Conclusion: Current glioblastoma cell treatment impacts on the subsequent activation of cDCs and T cells and should serve as basis for improving immunotherapeutic strategies of brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.